Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America (Q44464294)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America |
scientific article |
Statements
1 reference
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America (English)
1 reference
Sergio Poli-Bigelli
1 reference
Jose Rodrigues-Pereira
1 reference
Alexandra D Carides
1 reference
Guoguang Julie Ma
1 reference
Krista Eldridge
1 reference
Anita Hipple
1 reference
Judith K Evans
1 reference
Kevin J Horgan
1 reference
Francesca Lawson
1 reference
Aprepitant Protocol 054 Study Group
1 reference
1 June 2003
1 reference
Identifiers
1 reference